The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome

Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.
Journal of Medical Genetics (Impact Factor: 5.64). 05/2009; 46(7):447-50. DOI: 10.1136/jmg.2008.064766
Source: PubMed

ABSTRACT Deletion of the complement factor H related 1 (CFHR1) gene is a consequence of non-allelic homologous recombination and has been reported to be more frequent in atypical haemolytic uraemic syndrome (aHUS) patients than in the normal population. Therefore, it is considered a susceptibility factor for the disease. aHUS is associated with hereditary or acquired abnormalities that lead to uncontrolled alternative pathway complement activation. We tested the CFHR1 deletion for association with aHUS in a population of French aHUS cases and controls. Furthermore, we examined the effect of the deletion in the context of known aHUS risk factors.
177 aHUS patients and 70 healthy donors were studied. The number of CFHR1 alleles was quantified by multiplex ligation dependant probe amplification (MLPA). The frequency of the deleted allele was significantly higher in aHUS patients than in controls (22.7% vs 8.2%, p<0.001). The highest frequency was in the subgroup of patients exhibiting anti-factor H (FH) autoantibodies (92.9%, p<0.0001 vs controls) and in the group of patients exhibiting a factor I (CFI) gene mutation (31.8%, p<0.001 vs controls). The CFHR1 deletion was not significantly more frequent in the cohort of aHUS patients when patients with anti-FH IgG or CFI mutation were excluded.
The high frequency of CFHR1 deletion in aHUS patients is restricted to the subgroups of patients presenting with anti-FH autoantibodies or, to a lesser degree, CFI mutation. These results suggest that the CFHR1 deletion plays a secondary role in susceptibility to aHUS.

Download full-text


Available from: Catherine Sautès-Fridman, Jul 13, 2015
1 Follower
  • Source
    • "Gain-of-function mutations in genes that encode Complement Factor B (CFB) [20] and complement Component 3 (C3) [21] [22] have been identified in 1–2% and 10% of aHUS patients, respectively. Anti-CFH antibodies are detected in 5–10% of patients with aHUS, most often in association with a large deletion of CFHR1 [23] [24] [25]. The current multi-hit pathogenic paradigm proposes that aHUS occurs as a result of the interaction between exogenous endothelial-insulting factors, referred here as trigger events, and a genetic susceptibility predisposing to complement over-activation on endothelial surfaces [2] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Atypical hemolytic and uremic syndrome (aHUS) is associated with a high rate of recurrence and poor outcomes after kidney transplantation. Fortunately, recent advances in the understanding of the pathogenesis of aHUS have permitted an individualized risk assessment of post-transplant recurrence. Acquired or inherited dysregulation of the alternative complement pathway, thought to be the driving force of the disease, is identified in most aHUS patients. Notably, depending on the mutations involved, the risk of recurrence greatly varies, highlighting the importance of undertaking etiological investigations prior to kidney transplantation. In those with moderate to high risk of recurrence, the use of a prophylactic therapy, consisting in either plasmapheresis or eculizumab therapies, represents a major stride forward in the prevention of aHUS recurrence after kidney transplantation. In those who experience aHUS recurrence, a growing number of observations suggest that eculizumab therapy outperforms curative plasma therapy. The optimal duration of both prophylactic and curative therapies remains an important, yet unaddressed, issue. In this respect, the kidney transplant recipients, continuously exposed to endothelial-insulting factors, referred here as to triggers, might have a sustained high risk of recurrence. A global therapeutic approach should thus attempt to reduce exposure to these triggers.
    Transplantation reviews (Orlando, Fla.) 08/2013; 27. DOI:10.1016/j.trre.2013.07.003 · 2.68 Impact Factor
  • Source
    • "This remarkable finding suggests that binding of these FHR proteins, and capacity to regulate complement, directly or by complementing or competing with fH, can be beneficial or detrimental depending on the circumstances. The deletion of the CFHR1 and CFHR3 genes is likely also protective in aHUS (Abarrategui-Garrido et al. 2009; Martinez-Barricarte et al. 2012); however, the frequency of homozygosity for the CFHR3- CFHR1 deletion is increased in aHUS as a consequence of the association between complete deficiency of the FHR1 protein and the generation of anti-fH autoantibodies (Abarrategui-Garrido et al. 2009; Dragon-Durey et al. 2009; Jozsi et al. 2008; Moore et al. 2010; Zipfel et al. 2007). This is an intriguing association for which there is no clear explanation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: During the last decade, numerous studies have associated genetic variations in complement components and regulators with a number of chronic and infectious diseases. The functional characterization of these complement protein variants, in addition to recent structural advances in understanding of the assembly, activation and regulation of the AP C3 convertase, have provided important insights into the pathogenic mechanisms involved in some of these complement related disorders. This knowledge has identified potential targets for complement inhibitory therapies which are demonstrating efficacy and generating considerable expectation in changing the natural history of these diseases. Comprehensive understanding of the genetic and non-genetic risk factors contributing to these disorders will also result in targeting of the right patient groups in a stratified medicine approach through better diagnostics and individually tailored treatments, thereby improving management of patients.
    Immunobiology 11/2012; 217(11):1034-46. DOI:10.1016/j.imbio.2012.07.021 · 3.18 Impact Factor
  • Source
    • "More than one thousand aHUS patients screened for complement mutations have been reported from five European series [63] [64] [65] [66] [67] [68] [69] and one from the USA [70]. Mutations in the genes encoding regulatory proteins factor H (CFH), membrane cofactor protein (MCP), factor I (CFI) or thrombomodulin (THBD) have been demonstrated in 20–30%, 5–15%, 4–10% and 3–5% of patients respectively, and mutations in the genes encoding C3 convertase proteins, C3 and factor B (CFB), in 2–10% and 1–4% respectively [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73]. Up to 12% of patients have various combinations of two or more mutations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: 2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli -associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS. Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS.
    La Presse Médicale 03/2012; 41(3 Pt 2):e115-35. DOI:10.1016/j.lpm.2011.11.013 · 1.17 Impact Factor
Show more